CD33-targeted therapy

CD33-targeted therapy is an approach that treats certain blood cancers, like acute myeloid leukemia (AML), by directing treatments specifically to cancer cells. CD33 is a protein found on the surface of many leukemia cells. Therapeutic agents, such as targeted antibodies or antibody-drug conjugates, are designed to recognize and attach to CD33. This allows the treatment to deliver powerful drugs directly to the cancer cells, sparing most healthy cells and aiming to improve effectiveness while reducing side effects. By honing in on CD33, the therapy offers a more precise attack against the leukemia.